Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Yuchao Jin

Physician Assistant, Medical San Diego, CA Physician Assistant

NPI 1518454396 CMS profile 10905764

5030 Camino De La Siesta Ste 106, San Diego, CA 92108

Open in the dashboard

General payments

$21,914

1,049 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yuchao Jin of San Diego, CA is reported in the CMS Open Payments database as having received $21,914 across 1,049 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,355 333
2024 General $4,583 190
2023 General $3,510 181
2022 General $3,647 191
2021 General $2,820 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yuchao Jin
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Yuchao Jin were reported at $7,355. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Yuchao Jin Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,820 $156 $41–$563 $132
2022 $3,647 $185 $55–$649 $149
2023 $3,510 $199 $58–$717 $160
2024 $4,583 $206 $62–$740 $164
2025 $7,355 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,323 234 payments
  2. Amgen Inc. $4,033 208 payments
  3. UCB, Inc. $2,211 103 payments
  4. Janssen Biotech, Inc. $2,035 82 payments
  5. Novartis Pharmaceuticals Corporation $1,231 70 payments
  6. GlaxoSmithKline, LLC. $1,191 57 payments
  7. Lilly USA, LLC $924 36 payments
  8. Mallinckrodt Hospital Products Inc. $888 30 payments
  9. Aurinia Pharma U.S., Inc. $826 37 payments
  10. AstraZeneca Pharmaceuticals LP $794 42 payments
  11. Other $3,457 150 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $21,846 1,046 payments
  2. Education $67 3 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $3,528 196 payments
  2. TREMFYA $2,121 82 payments
  3. Otezla $1,189 66 payments
  4. Enbrel Inflammation $1,165 68 payments
  5. Bimzelx $1,162 46 payments
  6. BENLYSTA $1,116 56 payments
  7. Enbrel Inflammation $1,081 50 payments
  8. Cimzia $1,049 57 payments
  9. EVENITY $896 49 payments
  10. ACTHAR $888 30 payments
  11. Other $10,712 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

889

Median for Physician Assistant: 241

Drug cost

$1,006,155

Median for Physician Assistant: $4,110

Branded share of claims

29.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 33 $453,286
Enbrel Sureclick Etanercept Brand 20 $206,290
Rinvoq Upadacitinib Brand 30 $186,853
Xeljanz Xr Tofacitinib Citrate Brand 19 $117,111
Hadlima(Cf) Pushtouch Adalimumab-Bwwd Brand 11 $16,980
Hydroxychloroquine Sulfate Generic 160 $9,219
Methotrexate Methotrexate Sodium Brand 153 $4,247
Pregabalin Generic 20 $2,332
Celecoxib Generic 53 $2,160
Leflunomide Generic 28 $1,328

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$17,262

Of which drugs: $2,496

Medicare patients

94

Average age 72

Services billed

924

77 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Osteoporosis 38%
Depression 35%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 22%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$714 30 —
ACTHAR
$375 — —
COSENTYX
$234 — —
TREMFYA
$231 — —
Bimzelx
$227 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

1,049 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record